MyBlueDotsAlentis Announces Positive Topline Results from Two Studies of Lixudebart (ALE.F02) in Patients with ANCA-RPGN and Advanced Liver Fibrosis MyBlueDots4 months ago01 mins BASEL, Switzerland–(BUSINESS WIRE)–Demonstrated Robust Dose-Dependent Target Engagement, Preliminary Evidence of Improved Organ Function and a Favorable Safety Profile Post navigation Previous: Henry Schein Opens Customer Emergency Support Hotline in Response to California FiresNext: What Illinois residents should know, following the first US death from bird virus
TRIM63 identified as key gene in common heart disease, unlocking potential for earlier diagnosis MyBlueDots1 day ago 0
Newly discovered cells in connective tissue open up strategy against pancreatic cancer MyBlueDots1 day ago 0